Market research
SEEL Seelos Therapeutics Inc
OTCQB USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 215K
- P/E ratio
- 0.0
- Analyst target
- 120
- Dividend yield
- Not available
- Beta
- 1.94
Profile
Company facts
- Exchange
- OTCQB
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US81577F1093
- Market cap
- 215K
- P/E ratio
- 0.0
- Analyst target
- 120
- Dividend yield
- Not available
- Beta
- 1.94
About
About Seelos Therapeutics Inc
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York. On November 16, 2024, Seelos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the SEEL discussion.
5 years, 4 months ago
Seelos Therapeutics, Inc is currently in a long term uptrend where the price is trading 5.0% above its 200 day moving average.
From a valuation standpoint, the stock is 57.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 572.5.
Seelos Therapeutics, Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has increased by 37.3% to $-6M since the same quarter in the previous year.
Finally, its free cash flow grew by 35.0% to $-3M since the same quarter in the previous year.
Based on the above factors, Seelos Therapeutics, Inc gets an overall score of 4/5.